Comparative cardiovascular and renal effectiveness and safety of Empagliflozin and other SGLT2i in patients with type 2 diabetes (T2D), with and without baseline kidney disease in the United States First published 18/07/2022 Last updated 15/10/2026 EU PAS number:EUPAS45682 Study Finalised